Education
About Us
Working with TipRanks
Follow Us
CVRx (CVRX)
NASDAQ:CVRX
CVRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.81 - $18.55
Previous CloseN/A
Volume20.10K
Average Volume (3M)446.99K
Market Cap
$189.95M
Enterprise Value$257.65M
Total Cash (Recent Filing)$106.19M
Total Debt (Recent Filing)$7.09M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
May 08, 2025EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding26,056,808
10 Day Avg. Volume321,606
30 Day Avg. Volume446,992
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.00
Enterprise Value/Ebitda-4.33
Forecast
1Y Price Target
$16.83Price Target Upside130.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
CVRx News
PremiumCompany Announcements
CVRx’s Earnings Call: Growth Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Clinical DataReal-world evidence shows significant reduction in hospitalization, strengthening the use case of Barostim beyond quality-of-life improvements.
Financial PerformanceCVRx announced final Q4 revenue of $15.3M, showing a year-over-year increase of 36% and a quarter-over-quarter increase of 15%.
Growth PotentialCVRx is seen as an attractive buying opportunity into a high-growth medical device company fulfilling an unmet need in a $2.2B total addressable market.
Bears Say
Market CoverageThe number of sales territories decreased from 48 to 45, below the analyst's projected 51, indicating potential challenges in market coverage.
Sales PerformancePreliminary Q1 revenue was short of expectations due to a slower ramp-up from new reps and seasonal procedure softness.
ValuationThe price target is decreased from $23 to $18, reflecting a less favorable valuation based on updated market conditions and company performance expectations.
---
Ownership Overview
Currently, No data available
---
CVRX FAQ
What was CVRx’s price range in the past 12 months?
CVRx lowest stock price was $5.81 and its highest was $18.55 in the past 12 months.
What is CVRx’s market cap?
CVRx’s market cap is $189.95M.
When is CVRx’s upcoming earnings report date?
CVRx’s upcoming earnings report date is May 08, 2025 which is in 5 days.
How were CVRx’s earnings last quarter?
CVRx released its earnings results on Feb 04, 2025. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.375 by -$0.055.
Is CVRx overvalued?
According to Wall Street analysts CVRx’s price is currently Undervalued.
Does CVRx pay dividends?
CVRx does not currently pay dividends.
What is CVRx’s EPS estimate?
CVRx’s EPS estimate is -0.57.
How many shares outstanding does CVRx have?
CVRx has 26,056,808 shares outstanding.
What happened to CVRx’s price movement after its last earnings report?
CVRx reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.375. Following the earnings report the stock price went down -7.2%.
Which hedge fund is a major shareholder of CVRx?
Currently, no hedge funds are holding shares in CVRX
---
CVRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.83 (130.86% Upside)
$16.83 (130.86% Upside)
Blogger Sentiment
Bullish
CVRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 239.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.96%
12-Months-Change
Fundamentals
Return on Equity
-81.58%
Trailing 12-Months
Asset Growth
15.78%
Trailing 12-Months
Company Description
CVRx
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
---
CVRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and successful expansion in the U.S. market, alongside key reimbursement milestones and educational initiatives. However, challenges were noted in the European market, and there were increased operating expenses and interest expenses leading to a higher net loss.Read More>---
CVRX Stock 12 Month Forecast
Average Price Target
$16.83
▲(130.86% Upside)
Technical Analysis
---